Synmosa Biopharma Corporation provided earnings guidance for the year 2022. For the period, the company estimated that this year's annual revenue will increase by 36%, the gross profit rate will be 41.8%, and the net profit after tax will exceed TWD 820 million increase by 172%, EPS estimated at TWD 2.5.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
39.55 TWD | +1.15% | +2.06% | +2.33% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+2.33% | 465M | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- 4114 Stock
- News Synmosa Biopharma Corporation
- Synmosa Biopharma Corporation Provides Earnings Guidance for the Year 2022